MITOTANE Dosage and Mechanism

 Mitotane is a potent cancer medicine which is sold under the brand name LYSODREN. It is used in the treatment of patients with advanced adrenal cortical carcinoma, which is basically a kind of cancer of the outer layer of the adrenal gland. Mitotane is a cytotoxic agent which is used when cancer is inoperable, either functional or non-functional and relapsed. 

Patients with adrenal cortical carcinoma are low; hence it is considered 'rare', and LYSODREN is taken as an orphan medicine for this rare disease. It is available in India, and lysodren's price is economical and can be easily purchased by any authorized supplier against a valid prescription.

How to take Mitotane?

It is available as 500mg tablets, and the initial dose is 2 g to 6 g orally daily, in three or four divided doses, taken with meals containing fatty foods. Increase the dose incrementally to achieve a blood concentration of 14 to 20 mg/l, or as tolerated, and the levels of the active substance in the blood should be monitored frequently. 

Levels above 20 mg/L may cause severe side effects without increasing the medicine's effectiveness. The medicine should be taken till the time it is effective and must be withdrawn if there are any side effects. Indian Pharma Network is among the reliable platforms which facilitate patients' connection with genuine pharmaceutical suppliers, wholesalers, and dealers. To know more details about the cost of MITOTANE in India, contact us at https://indianpharmanetwork.in/contact-us/ 

There is limited information on the use of Lysodren in children, but a daily starting dose of 1.5 to 3.5 g per square meter of body surface area is recommended.

How does MITOTANE work?

Mitotane is a white granular solid composed of clear, colorless crystals. It is tasteless and has a slightly pleasant aromatic odour. Steroid hormones are produced by the cortex of the adrenal gland. When this area develops cancer, levels of these hormones can increase, which causes the symptoms of the disease. The active substance in Lysodren, Mitotane, is thought to work by inhibiting cells in the adrenal gland from working properly and by damaging their mitochondria, there is a reduction in some steroid hormones. It may also alter the breakdown of these hormones. Together, these effects reduce the levels of the hormones in the body, improving the symptoms of the disease. But the exact mechanism of this cytotoxic agent is still unknown. 

Patients taking recommended doses of Mitotane can get benefits fighting against this cancer, and Mitotane 500 mg tablets at economical prices can be obtained through Indian Pharma Network.

For more details about Mitotane, call us at our toll-free number, 18008891064; we will be happy to help you.

Trodelvy for unresectable locally advanced

 "Unresectable locally advanced" is a medical term that describes a situation where a cancerous tumor has grown to a point where it cannot be removed surgically. This can happen because the tumor has grown into or around vital organs, blood vessels, or nerves, making it too risky to attempt surgery.

In these cases, doctors may recommend other treatment options, such as radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of these. The goal of treatment is to shrink the tumor and slow down its growth, alleviate symptoms, improve quality of life, and potentially increase survival.

It is important for patients with unresectable locally advanced cancer to work closely with their healthcare team to determine the best treatment plan for their specific situation. They may also consider seeking a second opinion to ensure they are receiving the most appropriate care.

Trodelvy (sacituzumab govitecan-hziy) is a medication used to treat certain types of cancer. Specifically, it is used to treat adults with metastatic triple-negative breast cancer (TNBC) who have received at least two prior treatments for their disease. It is also used to treat adults with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Trodelvy is a type of medication called an antibody-drug conjugate. It works by targeting a protein called Trop-2, which is present on the surface of certain cancer cells. The medication is made up of two parts: an antibody that targets the Trop-2 protein and a chemotherapy drug that is attached to the antibody. When the medication attaches to the cancer cell, it releases the chemotherapy drug, which enters the cancer cell and destroys it.

The medication is given as an intravenous (IV) infusion, meaning it is administered directly into a vein over a period of time. The dosage and frequency of treatment will depend on the individual patient's condition and response to treatment.

Like all medications, Trodelvy can cause side effects. Common side effects may include fatigue, nausea, diarrhea, anemia, hair loss, and decreased appetite. More serious side effects may include infections, bleeding, and infusion-related reactions. It is important for patients receiving this treatment to discuss potential side effects with their healthcare provider and report any concerning symptoms promptly.

Triple-negative breast cancer Treatment

 Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is more aggressive and difficult to treat than other types of breast cancer, as it does not respond to hormonal therapies or targeted therapies that are effective against ER-positive, PR-positive, or HER2-positive breast cancers.

The treatment of TNBC depends on the stage of cancer and other individual factors such as age, overall health, and personal preferences. The main treatment options for TNBC include:

• Surgery: Surgery is usually the first treatment for TNBC. The aim of surgery is to remove as much cancer as possible. This may involve a lumpectomy (removal of the tumor and a surrounding margin of healthy tissue) or a mastectomy (removal of the entire breast).

• Chemotherapy: Chemotherapy is often used after surgery to reduce the risk of cancer coming back. It may also be used as the primary treatment for TNBC that has spread beyond the breast. Chemotherapy drugs are given intravenously or orally and are designed to kill cancer cells.

• Radiation therapy: Radiation therapy uses high-energy beams to destroy cancer cells. It is often given after surgery to kill any remaining breast or lymph nodes cancer cells. It may also be used to relieve symptoms of advanced TNBC.

• Immunotherapy: Immunotherapy is a targeted therapy that stimulates the immune system to attack cancer cells. Pembrolizumab and atezolizumab are two immunotherapy drugs that have been approved for use in combination with chemotherapy for the treatment of advanced TNBC.

• Clinical trials: There are ongoing clinical trials investigating new treatments for TNBC, including targeted therapies and immunotherapies.

It is essential to work closely with a team of healthcare professionals to determine the best treatment plan for TNBC.